Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

University of Minnesota, 2021 NCT04311177

angiotensin receptor blockers (ARBs) (n=58) vs. placebo (n=59)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Losartan
Losartan 25 mg orally twice daily unless estimated glomerular filtration rate, eGFR, was reduced, when dosing was reduced to once daily.

Control treatment

Placebo

Patients

COVID 19 outpatients

presumptive positive laboratory test for SARS-coV-2 or upper respiratory infection with recent exposure to laboratory-proven SARS-coV-2-infected personnegative influenza and respiratory virus panel

Method

Double-blind.

3 hospitals in Minnesota, United States.

Remark

ACEI-COVID (Bauer), 2021 NCT04353596

discontinuation of ACEI/ARB (n=104) vs. continuation of ACEI/ARB (n=100)

randomized controlled trial   some concerns about risk of bias

Studied treatment

discontinuation of RAS inhibition

Control treatment

continuation of RAS inhibition

Patients

COVID 19 outpatients

Method

open-label

35 centres in Austria and Germany

Remark